As reimbursement approaches shift, healthcare organizations will need better information on their costs and how to set prices for patients. Results of a recent study indicate they have a long way to go.
Attaining true transparency in drug trials calls for a better solution than excessive redaction. Learn the drawbacks and benefits of the different methods for anonymization in clinical trials. There is potential for strong industry leaders to emerge — so long as they align themselves with best practice guidelines. By making the right choices now, pharmaceutical organizations will meet the new transparency mandates while complying with privacy regulations and maximizing the quality of data that can be shared for secondary purposes.